BackgroundAlthough patients with COVID-19 have a higher risk of acute ischemic stroke (AIS), the impact on stroke outcomes remains uncertain.AimsTo determine the clinical outcomes of patients with AIS and COVID-19 (AIS-COVID+).MethodsWe performed a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. Our protocol was registered with the International Prospective Register of Systematic Reviews (CRD42020211977). Systematic searches were last performed on June 3, 2021 in EMBASE, PubMed, Web-of-Science, Scopus, and CINAHL Databases. Inclusion criteria: (1) studies reporting outcomes on AIS-COVID+; (2) original articles published in 2020 or later; (3) study participants aged ≥18 years. Exclusion criteria: (1) case reports with <5 patients, abstracts, review articles; (2) studies analyzing novel interventions. Risk of bias was assessed using the Mixed Methods Appraisal Tool. Random-effects models estimated the pooled OR and 95% confidence intervals (95% CI) for mortality, modified Rankin Scale (mRS) score, length of stay (LOS), and discharge disposition.ResultsOf the 43 selected studies, 46.5% (20/43) reported patients with AIS without COVID-19 (AIS-COVID−) for comparison. Random-effects model included 7294 AIS-COVID+ and 158 401 AIS-COVID−. Compared with AIS-COVID−, AIS-COVID+ patients had higher in-hospital mortality (OR=3.87 (95% CI 2.75 to 5.45), P<0.001), less mRS scores 0–2 (OR=0.53 (95% CI 0.46 to 0.62), P<0.001), longer LOS (mean difference=4.21 days (95% CI 1.96 to 6.47), P<0.001), and less home discharge (OR=0.31 (95% CI 0.21 to 0.47), P<0.001).ConclusionsPatients with AIS-COVID had worse outcomes, with almost fourfold increased mortality, half the odds of mRS scores 0–2, and one-third the odds of home discharge. These findings confirm the significant impact of COVID-19 on early stroke outcomes.

No abstract